Anteris Technologies Global (NASDAQ:AVR) Major Shareholder L1 Capital Pty Ltd Buys 272,695 Shares of Company Stock

Anteris Technologies Global Corp. (NASDAQ:AVR) major shareholder L1 Capital Pty Ltd acquired 272,695 shares of the business’s stock in a transaction on Tuesday, October 6th. The stock was bought at an average cost of $7.18 per share, for a total transaction of $1,957,950.10. Following the completion of the transaction, the insider directly owned 6,358,271 shares of the company’s stock, valued at $45,652,385.78. This trade represents a 4.48% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

L1 Capital Pty Ltd also recently made the following trade(s):

• On Monday, October 5th, L1 Capital Pty Ltd bought 648,455 shares of Anteris Technologies Global stock. The stock was bought at an average cost of $7.51 per share, with a total value of $4,869,897.05.
• On Friday, October 2nd, L1 Capital Pty Ltd bought 236,354 shares of Anteris Technologies Global stock. The stock was bought at an average price of $7.78 per share, with a total value of $1,838,834.12.
• On Thursday, October 1st, L1 Capital Pty Ltd bought 322,940 shares of Anteris Technologies Global stock. The shares were bought at an average price of $7.60 per share, for a total transaction of $2,454,344.00.
• On Wednesday, September 30th, L1 Capital Pty Ltd purchased 74,286 shares of Anteris Technologies Global stock. The shares were bought at an average cost of $7.72 per share, for a total transaction of $573,487.92.
• On Friday, August 28th, L1 Capital Pty Ltd sold 7,800 shares of Anteris Technologies Global stock. The stock was sold at an average price of $8.83, for a total value of $68,874.00.
• On Tuesday, August 11th, L1 Capital Pty Ltd sold 375,815 shares of Anteris Technologies Global stock. The shares were sold at an average price of $9.30, for a total transaction of $3,495,079.50.
• On Monday, August 10th, L1 Capital Pty Ltd sold 251,844 shares of Anteris Technologies Global stock. The shares were sold at an average price of $9.10, for a total transaction of $2,291,780.40.
• On Thursday, August 6th, L1 Capital Pty Ltd sold 174,721 shares of Anteris Technologies Global stock. The stock was sold at an average price of $8.10, for a total transaction of $1,415,240.10.
• On Tuesday, August 4th, L1 Capital Pty Ltd sold 480,608 shares of Anteris Technologies Global stock. The shares were sold at an average price of $8.30, for a total transaction of $3,989,046.40.
• On Wednesday, August 5th, L1 Capital Pty Ltd sold 14,581 shares of Anteris Technologies Global stock. The shares were sold at an average price of $8.23, for a total transaction of $120,001.63.

Anteris Technologies Global Trading Down 2.8%

AVR opened at $6.63 on Friday. Anteris Technologies Global Corp. has a twelve month low of $3.30 and a twelve month high of $11.06. The firm has a market cap of $646.16 million, a price-to-earnings ratio of -3.40 and a beta of 1.87. The company has a fifty day simple moving average of $8.41 and a 200 day simple moving average of $8.03.

Anteris Technologies Global (NASDAQ:AVR) last issued its quarterly earnings data on Tuesday, August 11th. The company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.09). The firm had revenue of $1.01 million during the quarter, compared to analyst estimates of $1.50 million. Anteris Technologies Global had a negative return on equity of 77.69% and a negative net margin of 4,619.27%.During the same quarter in the prior year, the firm earned ($0.58) EPS. On average, analysts forecast that Anteris Technologies Global Corp. will post -1.21 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages recently commented on AVR. Barclays raised Anteris Technologies Global to a “hold” rating in a report on Wednesday. Cantor Fitzgerald restated an “overweight” rating and set a $15.00 price objective on shares of Anteris Technologies Global in a report on Friday, August 14th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Anteris Technologies Global in a research report on Wednesday, August 26th. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $14.00.

Key Headlines Impacting Anteris Technologies Global

Here are the key news stories impacting Anteris Technologies Global this week:

• Positive Sentiment: Major shareholder continued buying. L1 Capital purchased 272,695 AVR shares for approximately $1.96 million at an average price of $7.18, increasing its position by 4.48%. This follows several additional purchases in late September and early October, signaling continued confidence from a significant investor. SEC filing on L1 Capital’s AVR purchase
• Neutral Sentiment: Barclays initiated coverage with a Hold-equivalent view. Barclays’ reported “Hold” or “Equal Weight” stance suggests the firm sees limited near-term evidence for a stronger bullish recommendation. The coverage provides additional visibility but is unlikely to be a major catalyst by itself. Barclays AVR rating report
• Neutral Sentiment: Share and incentive-plan records were updated. Anteris reported changes involving CHESS Depositary Interests and employee equity incentives. These administrative updates do not provide a new clinical or commercial catalyst, though investors will monitor their effect on the share count. Anteris CDI and equity incentive update
• Negative Sentiment: Expanded unquoted equity may raise dilution concerns. The employee incentive-plan announcement adds to investor attention on potential future share issuance. For a clinical-stage company that is not yet profitable, the prospect of additional equity compensation or dilution can weigh on sentiment. Anteris employee incentive-plan announcement

Hedge Funds Weigh In On Anteris Technologies Global

A number of institutional investors and hedge funds have recently bought and sold shares of AVR. BlackRock Inc. acquired a new stake in shares of Anteris Technologies Global in the 2nd quarter worth approximately $56,846,000. ADAR1 Capital Management LLC increased its stake in shares of Anteris Technologies Global by 205.9% during the first quarter. ADAR1 Capital Management LLC now owns 3,789,132 shares of the company’s stock valued at $21,030,000 after acquiring an additional 2,550,355 shares during the period. Perceptive Advisors LLC increased its stake in shares of Anteris Technologies Global by 104.4% during the first quarter. Perceptive Advisors LLC now owns 3,425,476 shares of the company’s stock valued at $19,011,000 after acquiring an additional 1,750,000 shares during the period. Nantahala Capital Management LLC bought a new stake in Anteris Technologies Global during the second quarter worth approximately $33,325,850. Finally, Affinity Asset Advisors LLC lifted its position in Anteris Technologies Global by 87.5% in the first quarter. Affinity Asset Advisors LLC now owns 912,397 shares of the company’s stock worth $5,064,000 after purchasing an additional 425,713 shares during the period.

Anteris Technologies Global Company Profile

Anteris Technologies Global is a clinical-stage structural heart company developing technologies intended to treat aortic valve disease. The company’s lead product is the DurAVR transcatheter heart valve, which is designed to replicate the performance characteristics of a healthy human aortic valve and restore more natural blood flow.

Anteris uses its proprietary ADAPT tissue-engineering technology to create heart-valve materials designed for durability and biocompatibility. The company is focused primarily on transcatheter aortic valve replacement and related structural-heart applications, with its products progressing through clinical development and regulatory evaluation rather than broad commercial distribution.

The company has Australian origins and maintains operations and clinical-development activities in both Australia and the United States.